Supplemental figure S4 from Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States

作者：Curtis A. Lachowiez, Georgios Asimomitis, Elsa Bernard, Sean M. Devlin, Yanis Tazi, Maria Creignou, Ulrich Germing, Norbert Gattermann, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Luca Malcovati, Jad Othman, Richard Dillon, Ann‐Kathrin Eisfeld, Deedra Nicolet, Ghayas C. Issa, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Nigel H. Russell, Mario Cazzola, Hartmut Döhner, Brian J.P. Huntly, Robert P. Hasserjian, Eva Hellström‐Lindberg, Elli Papaemmanuil, Sanam Loghavi · 年份：2026 · DOI：10.1158/2643-3230.32728255 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Chronic Myeloid Leukemia Treatments

<p>Comparison of SF3B1-mutated MDS with del(5q) to subclonal SF3B1-mutated MDS without del(5q). (A-F) No significant differences in baseline clinical demographics or SF3B1 VAF were observed between cases with vs. without del(5q). (G,H) Whilst survival was superior in patients with clonal SF3B1 mutations, no significant difference in leukemia-free or overall survival was identified between cases of SF3B1-mutated MDS with del(5q) vs. subclonal SF3B1-mutated MDS without del(5q), suggesting survival outcomes in such cases are influenced by alternative molecular driver events. Reported p-values utilized the cox model Wald test.</p>